<Disease><Name>GLYCOGEN STORAGE DISEASE TYPE II. INFANTILE ONSET. POMPE DISEASE</Name><Synonym>GSD2; GLYCOGEN STORAGE DISEASE II</Synonym><OMIM><Number>232300</Number><URL>http://omim.org/entry/232300</URL></OMIM><Orphanet><Number>308552</Number><URL>http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&amp;Expert=308552</URL></Orphanet><Protein><Number>Lysosomal alpha-glucosidase</Number><URL>http://www.uniprot.org/uniprot/P10253</URL></Protein><ExPASy><Number>3.2.1.3</Number><URL>http://enzyme.expasy.org/EC/3.2.1.3</URL></ExPASy><Gene>17q25.3</Gene><ICD>E74.0</ICD><Summary>rare (1:100000 );autosomal recessive ;mutation in the GAA gene;1) infantile onset: cardiomegaly, progressive weakness, macroglossia;2) juvenile onset: (cardiac involvement), slower progression 3) adult onset: slowly progressive myopathy</Summary><Symptoms><symtomp><id>1877</id><symptom>cardiomegaly</symptom><category>CARDIOVASCULAR SYSTEM</category></symtomp><symtomp><id>2104</id><symptom>cardiomyopathy</symptom><category>CARDIOVASCULAR SYSTEM</category></symtomp><symtomp><id>3677</id><symptom>cardiomyopathy, hypertrophic</symptom><category>CARDIOVASCULAR SYSTEM</category></symtomp><symtomp><id>2423</id><symptom>early death</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>1883</id><symptom>ECG abnormalities [-]</symptom><category>LABORATORY FINDINGS</category></symtomp><symtomp><id>1979</id><symptom>feeding difficulties, poor feeding</symptom><category>GASTROINTESTINAL SYSTEM | GASTROINTESTINAL SYSTEM</category></symtomp><symtomp><id>2433</id><symptom>hearing defect, deafness</symptom><category>EARS | NERVOUS SYSTEM</category></symtomp><symtomp><id>1878</id><symptom>heart failure, cardiac failure</symptom><category>CARDIOVASCULAR SYSTEM</category></symtomp><symtomp><id>1994</id><symptom>hepatomegaly (large liver)</symptom><category>GASTROINTESTINAL SYSTEM</category></symtomp><symtomp><id>2356</id><symptom>hydrops fetalis</symptom><category>GENERAL TOPICS | IMMUNE OR HEMATOLOGIC SYSTEM</category></symtomp><symtomp><id>1897</id><symptom>hypotonia</symptom><category>MUSCLES | NERVOUS SYSTEM</category></symtomp><symtomp><id>1715</id><symptom>infections (severe or recurrent)</symptom><category>GENERAL TOPICS | IMMUNE OR HEMATOLOGIC SYSTEM</category></symtomp><symtomp><id>1852</id><symptom>macroglossia, large/protuding tongue</symptom><category>HEAD</category></symtomp><symtomp><id>1787</id><symptom>muscle weakness</symptom><category>MUSCLES</category></symtomp><symtomp><id>1786</id><symptom>myopathy</symptom><category>MUSCLES</category></symtomp><symtomp><id>2507</id><symptom>onset, childhood / childhood</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2505</id><symptom>onset, infancy / infancy</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2504</id><symptom>onset, neonatal / neonatal</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>1890</id><symptom>progressive muscle defect</symptom><category>MUSCLES</category></symtomp><symtomp><id>2143</id><symptom>respiratory insufficiency / respiratory failure</symptom><category>LUNG OR RESPIRATORY SYSTEM</category></symtomp></Symptoms><Metabolites><metabolite><id>963</id><name>alpha-Glucosidase</name><specimen>fibroblasts</specimen><value>decreased</value><min>    </min><max>100.00</max><unit>% activity</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>964</id><name>alpha-Glucosidase</name><specimen>muscle</specimen><value>decreased</value><min>    </min><max>100.00</max><unit>% activity</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>418</id><name>Aspartate aminotransferase (ASAT, SGOT)</name><specimen>serum</specimen><value>decreased</value><min>10.00</min><max>50.00</max><unit>U/l</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>694</id><name>Creatine kinase</name><specimen>serum</specimen><value>decreased</value><min>40.00</min><max>400.00</max><unit>U/l</unit><age>child</age><method /><comment /></metabolite><metabolite><id>309</id><name>Creatine kinase</name><specimen>serum</specimen><value>decreased</value><min>40.00</min><max>150.00</max><unit>U/l</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>308</id><name>Creatine kinase</name><specimen>serum</specimen><value>decreased</value><min>60.00</min><max>400.00</max><unit>U/l</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>947</id><name>Creatine kinase</name><specimen>serum</specimen><value>decreased</value><min>25.00</min><max>90.00</max><unit>U/l</unit><age>adult</age><method /><comment /></metabolite><metabolite><id>965</id><name>Oligosaccharides</name><specimen>urine</specimen><value>increased</value><min>    </min><max>    </max><unit>not detectable</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>416</id><name>Transaminases (ASAT/ALAT)</name><specimen>serum</specimen><value>increased</value><min>10.00</min><max>30.00</max><unit>U/l</unit><age>child</age><method /><comment /></metabolite></Metabolites><Literatures><literature><id>7390</id><title>Two-Tiered Newborn Screening with Post-Analytical Tools for Pompe Disease and Mucopolysaccharidosis Type I Results in Performan</title><author>Hall PL,</author><journal>Int J Neonatal Screem</journal><year>2020</year><book /><volume>6</volume><number>1</number><pages /><co_aut>et al.</co_aut></literature><literature><id>7391</id><title>Enzyme replacement therapy desensitization in a child with infantile onset Pompe disease</title><author>Toh TSW,</author><journal>Asian Pac J Allergy Immunol</journal><year>2020</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>7392</id><title>Identification of two novel variants in GAA underlying infantile-onset Pompe disease in two Pakistani families</title><author>Ullah A,</author><journal>J Pediatr Endocrinol Metab</journal><year>2020</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>6035</id><title>Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy</title><author>van der Meijden JC,</author><journal>J Inherit Metab Dis</journal><year>2018</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>7389</id><title>Pompe Disease: From Basic Science to Therapy</title><author>Kohler L,</author><journal>Neurotherapeutics</journal><year>2018</year><book /><volume>15</volume><number>4</number><pages>928-942</pages><co_aut>Puertollano R, Raben N</co_aut></literature><literature><id>4024</id><title>Quantification of muscle pathology in infantile Pompe disease</title><author>Schaenzer A,</author><journal>Neuromuscul Disord</journal><year>2017</year><book /><volume>27</volume><number>2</number><pages>141-152</pages><co_aut>et al.</co_aut></literature><literature><id>4026</id><title>Cardiac response to enzyme replacement therapy in infantile Pompe disease with severe hypertrophic cardiomyopathy</title><author>Avula S,</author><journal>Echocardiography</journal><year>2017</year><book /><volume>34</volume><number>4</number><pages>621-624</pages><co_aut>et al.</co_aut></literature><literature><id>4028</id><title>Metabolomic Profiling of Pompe Disease-Induced Pluripotent Stem Cell-Derived Cardiomyocytes Reveals That Oxidative Stress Is Associated With Cardiac and Skeletal Muscle Pathol</title><author>Sato Y,</author><journal>Stem Cells Transl Med</journal><year>2017</year><book /><volume>6</volume><number>1</number><pages>31-39</pages><co_aut>et al.</co_aut></literature><literature><id>4025</id><title>Pompe Disease: Diagnosis and Management. Evidence-Based Guidelines from a Canadian Expert Panel</title><author>Tarnopolsky M,</author><journal>Can J Neurol Sci</journal><year>2016</year><book /><volume>43</volume><number>4</number><pages>472-485</pages><co_aut>et al.</co_aut></literature><literature><id>4027</id><title>Cognitive Development in Infantile-Onset Pompe Disease Under Very Early Enzyme Replacement Therapy</title><author>Lai CJ,</author><journal>J Child Neurol</journal><year>2016</year><book /><volume>31</volume><number>4</number><pages>1617-1621</pages><co_aut>et al.</co_aut></literature><literature><id>4034</id><title>Elevated Plasma Cardiac Troponin T Levels Caused by Skeletal Muscle Damage in Pompe Disease</title><author>Wens SC,</author><journal>Circ Cardiovasc Genet</journal><year>2016</year><book /><volume>9</volume><number>1</number><pages>6-13</pages><co_aut>et al.</co_aut></literature><literature><id>2714</id><title>Glycogen storage disease types I and II: treatment updates</title><author>Koeberl DD</author><journal>J Inher Met Dis</journal><year>2007</year><book /><volume>30</volume><number>0</number><pages>159-164</pages><co_aut>et al.</co_aut></literature><literature><id>2204</id><title>Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk</title><author>Van den Hout JM</author><journal>Pediatrics</journal><year>2004</year><book /><volume>113</volume><number>5</number><pages>e448-457</pages><co_aut>et al.</co_aut></literature><literature><id>1127</id><title>Recombinant human alpha-glucosidase from rabbit milk in Pompe patients</title><author>Van den Hout H</author><journal>Lancet</journal><year>2000</year><book /><volume>356</volume><number>0</number><pages>397-398</pages><co_aut>et al.</co_aut></literature><literature><id>1128</id><title>Approach to gene therapy of glycogenosis type II (Pompe disease)</title><author>Poenaru L</author><journal>Mol Genet Metab</journal><year>2000</year><book /><volume>70</volume><number>0</number><pages>163-169</pages><co_aut /></literature><literature><id>144</id><title>Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency</title><author>Hirschhorn R</author><journal>The metabolic and molecular bases of inherited disease, 7/e; Editors: C.R.Scriver, A.L.Beaudet, W.S.Sly, D.Valle; McGraw-Hill Inc.</journal><year>1995</year><book /><volume>2</volume><number>0</number><pages>2443-2464</pages><co_aut /></literature></Literatures></Disease>